Table 1 Open in new tab Clinical,...

			QRS
Group-A
1	58	F	NSVT	r	R	R	QS	qr	R	rS	V3–V4	119	1.54	0.86	30
2	76	M	VPC	r	R	R	QS	qr	R	rS	V2–V3	124	1.44	0.88	25
3	60	M	NSVT	r	R	R	QS	rs	R	rS	V3–V4	127	0.96	0.74	21
4	74	F	VPC	R	R	Rs	QS	r	Rs	QS	V2–V3	121	0.6	0.58	24
5	43	F	NSVT	R	R	R	QS	r	R	rS	V2–V3	132	0.89	0.70	17
6	23	M	VPC	r	R	R	QS	qs	R	QS	V3–V4	128	1.14	0.87	20
7	39	F	VPC	r	R	R	QS	qs	R	QS	V2–V3	125	1.37	0.80	19
8	57	M	VPC	r	R	R	QS	rs	R	rS	V3–V4	136	1	0.74	19

Group-B
1	74	M	NSVT	R	R	rs	QS	R	R	QS	V3–V4	125	0.61	0.43	26
2	62	F	VPC	r	R	R	QS	qs	R	QS	V2–V3	133	0.90	0.80	20
3	64	M	VPC	R	Rs	Rs	QS	qR	Rs	QS	V2–V3	120	0.97	0.67	18
4	53	F	VPC	R	Rs	RS	QS	rsR	Rs	QS	V2–V3	123	0.87	0.59	30
5	64	M	VPC	R	R	rs	QS	r	Rs	QS	V2–V3	122	0.63	0.51	24
6	68	M	NSVT	R	Rs	RS	QS	qR	Rs	QS	V2–V3	119	0.90	0.50	26
7	76	M	NSVT	R	R	RS	QS	qr	R	QS	V3–V4	128	0.70	0.66	20
8	62	F	VPC	R	R	rS	QS	R	Rs	QS	V3–V4	125	0.65	0.28	22
9	71	M	VPC	R	R	qrS	QS	R	qrS	QS	V3–V4	126	0.37	0.16	24
10	69	M	VPC	r	R	Rs	QS	qr	R	QS	V3–V4	120	0.78	0.65	20
11	67	F	VPC	R	R	Rs	QS	qR	Rs	QS	V2–V3	134	0.91	0.77	16
12	84	M	VPC	R	R	QS	QS	R	QS	QS	V3–V4	122	0.12	0	18
13	79	M	VPC	R	R	Rs	QS	rsr	Rs	QS	V2–V3	121	0.88	0.78	22
14	85	M	VPC	R	R	qrS	QS	R	qrS	QS	V2–V3	129	0.33	0.17	20
15	82	F	VPC	r	R	Rs	QS	qr	R	QS	V2–V3	119	0.89	0.5	28
16	64	F	VPC	R	Rs	rS	QS	rsR	Rs	QS	V2–V3	118	0.83	0.53	29
17	72	F	NSVT	R	R	rs	QS	R	R	QS	V3–V4	124	0.73	0.50	28

QRS

Patients

Age (years)

Sex

Type

IIII

aVR

aVL

aVF

Transition

Duration (ms)

R amplitude (mV)

III/II ratio

V-QRS His (ms)

Group-A

NSVT

V3–V4

119

1.54

0.86

VPC

V2–V3

124

1.44

0.88

NSVT

V3–V4

127

0.96

0.74

VPC

V2–V3

121

0.6

0.58

NSVT

V2–V3

132

0.89

0.70

VPC

V3–V4

128

1.14

0.87

VPC

V2–V3

125

1.37

0.80

VPC

V3–V4

136

0.74

Group-B

NSVT

V3–V4

125

0.61

0.43

VPC

V2–V3

133

0.90

0.80

VPC

V2–V3

120

0.97

0.67

VPC

rsR

V2–V3

123

0.87

0.59

VPC

V2–V3

122

0.63

0.51

NSVT

V2–V3

119

0.90

0.50

NSVT

V3–V4

128

0.70

0.66

VPC

V3–V4

125

0.65

0.28

VPC

qrS

V3–V4

126

0.37

0.16

VPC

V3–V4

120

0.78

0.65

VPC

V2–V3

134

0.91

0.77

VPC

V3–V4

122

0.12

VPC

rsr

V2–V3

121

0.88

0.78

VPC

qrS

V2–V3

129

0.33

0.17

VPC

V2–V3

119

0.89

0.5

VPC

rsR

V2–V3

118

0.83

0.53

NSVT

V3–V4

124

0.73

0.50

			QRS
Group-A
1	58	F	NSVT	r	R	R	QS	qr	R	rS	V3–V4	119	1.54	0.86	30
2	76	M	VPC	r	R	R	QS	qr	R	rS	V2–V3	124	1.44	0.88	25
3	60	M	NSVT	r	R	R	QS	rs	R	rS	V3–V4	127	0.96	0.74	21
4	74	F	VPC	R	R	Rs	QS	r	Rs	QS	V2–V3	121	0.6	0.58	24
5	43	F	NSVT	R	R	R	QS	r	R	rS	V2–V3	132	0.89	0.70	17
6	23	M	VPC	r	R	R	QS	qs	R	QS	V3–V4	128	1.14	0.87	20
7	39	F	VPC	r	R	R	QS	qs	R	QS	V2–V3	125	1.37	0.80	19
8	57	M	VPC	r	R	R	QS	rs	R	rS	V3–V4	136	1	0.74	19

Group-B
1	74	M	NSVT	R	R	rs	QS	R	R	QS	V3–V4	125	0.61	0.43	26
2	62	F	VPC	r	R	R	QS	qs	R	QS	V2–V3	133	0.90	0.80	20
3	64	M	VPC	R	Rs	Rs	QS	qR	Rs	QS	V2–V3	120	0.97	0.67	18
4	53	F	VPC	R	Rs	RS	QS	rsR	Rs	QS	V2–V3	123	0.87	0.59	30
5	64	M	VPC	R	R	rs	QS	r	Rs	QS	V2–V3	122	0.63	0.51	24
6	68	M	NSVT	R	Rs	RS	QS	qR	Rs	QS	V2–V3	119	0.90	0.50	26
7	76	M	NSVT	R	R	RS	QS	qr	R	QS	V3–V4	128	0.70	0.66	20
8	62	F	VPC	R	R	rS	QS	R	Rs	QS	V3–V4	125	0.65	0.28	22
9	71	M	VPC	R	R	qrS	QS	R	qrS	QS	V3–V4	126	0.37	0.16	24
10	69	M	VPC	r	R	Rs	QS	qr	R	QS	V3–V4	120	0.78	0.65	20
11	67	F	VPC	R	R	Rs	QS	qR	Rs	QS	V2–V3	134	0.91	0.77	16
12	84	M	VPC	R	R	QS	QS	R	QS	QS	V3–V4	122	0.12	0	18
13	79	M	VPC	R	R	Rs	QS	rsr	Rs	QS	V2–V3	121	0.88	0.78	22
14	85	M	VPC	R	R	qrS	QS	R	qrS	QS	V2–V3	129	0.33	0.17	20
15	82	F	VPC	r	R	Rs	QS	qr	R	QS	V2–V3	119	0.89	0.5	28
16	64	F	VPC	R	Rs	rS	QS	rsR	Rs	QS	V2–V3	118	0.83	0.53	29
17	72	F	NSVT	R	R	rs	QS	R	R	QS	V3–V4	124	0.73	0.50	28

Table 1

Open in new tab

Clinical, electrophysiological, and electrocardiographic characteristics

			QRS
Patients	Age (years)	Sex	Type	I	II	IIII	aVR	aVL	aVF	V1	Transition	Duration (ms)	R amplitude (mV)	III/II ratio	V-QRS His (ms)
Group-A
1	58	F	NSVT	r	R	R	QS	qr	R	rS	V3–V4	119	1.54	0.86	30
2	76	M	VPC	r	R	R	QS	qr	R	rS	V2–V3	124	1.44	0.88	25
3	60	M	NSVT	r	R	R	QS	rs	R	rS	V3–V4	127	0.96	0.74	21
4	74	F	VPC	R	R	Rs	QS	r	Rs	QS	V2–V3	121	0.6	0.58	24
5	43	F	NSVT	R	R	R	QS	r	R	rS	V2–V3	132	0.89	0.70	17
6	23	M	VPC	r	R	R	QS	qs	R	QS	V3–V4	128	1.14	0.87	20
7	39	F	VPC	r	R	R	QS	qs	R	QS	V2–V3	125	1.37	0.80	19
8	57	M	VPC	r	R	R	QS	rs	R	rS	V3–V4	136	1	0.74	19

Group-B
1	74	M	NSVT	R	R	rs	QS	R	R	QS	V3–V4	125	0.61	0.43	26
2	62	F	VPC	r	R	R	QS	qs	R	QS	V2–V3	133	0.90	0.80	20
3	64	M	VPC	R	Rs	Rs	QS	qR	Rs	QS	V2–V3	120	0.97	0.67	18
4	53	F	VPC	R	Rs	RS	QS	rsR	Rs	QS	V2–V3	123	0.87	0.59	30
5	64	M	VPC	R	R	rs	QS	r	Rs	QS	V2–V3	122	0.63	0.51	24
6	68	M	NSVT	R	Rs	RS	QS	qR	Rs	QS	V2–V3	119	0.90	0.50	26
7	76	M	NSVT	R	R	RS	QS	qr	R	QS	V3–V4	128	0.70	0.66	20
8	62	F	VPC	R	R	rS	QS	R	Rs	QS	V3–V4	125	0.65	0.28	22
9	71	M	VPC	R	R	qrS	QS	R	qrS	QS	V3–V4	126	0.37	0.16	24
10	69	M	VPC	r	R	Rs	QS	qr	R	QS	V3–V4	120	0.78	0.65	20
11	67	F	VPC	R	R	Rs	QS	qR	Rs	QS	V2–V3	134	0.91	0.77	16
12	84	M	VPC	R	R	QS	QS	R	QS	QS	V3–V4	122	0.12	0	18
13	79	M	VPC	R	R	Rs	QS	rsr	Rs	QS	V2–V3	121	0.88	0.78	22
14	85	M	VPC	R	R	qrS	QS	R	qrS	QS	V2–V3	129	0.33	0.17	20
15	82	F	VPC	r	R	Rs	QS	qr	R	QS	V2–V3	119	0.89	0.5	28
16	64	F	VPC	R	Rs	rS	QS	rsR	Rs	QS	V2–V3	118	0.83	0.53	29
17	72	F	NSVT	R	R	rs	QS	R	R	QS	V3–V4	124	0.73	0.50	28

			QRS
Patients	Age (years)	Sex	Type	I	II	IIII	aVR	aVL	aVF	V1	Transition	Duration (ms)	R amplitude (mV)	III/II ratio	V-QRS His (ms)
Group-A
1	58	F	NSVT	r	R	R	QS	qr	R	rS	V3–V4	119	1.54	0.86	30
2	76	M	VPC	r	R	R	QS	qr	R	rS	V2–V3	124	1.44	0.88	25
3	60	M	NSVT	r	R	R	QS	rs	R	rS	V3–V4	127	0.96	0.74	21
4	74	F	VPC	R	R	Rs	QS	r	Rs	QS	V2–V3	121	0.6	0.58	24
5	43	F	NSVT	R	R	R	QS	r	R	rS	V2–V3	132	0.89	0.70	17
6	23	M	VPC	r	R	R	QS	qs	R	QS	V3–V4	128	1.14	0.87	20
7	39	F	VPC	r	R	R	QS	qs	R	QS	V2–V3	125	1.37	0.80	19
8	57	M	VPC	r	R	R	QS	rs	R	rS	V3–V4	136	1	0.74	19

Group-B
1	74	M	NSVT	R	R	rs	QS	R	R	QS	V3–V4	125	0.61	0.43	26
2	62	F	VPC	r	R	R	QS	qs	R	QS	V2–V3	133	0.90	0.80	20
3	64	M	VPC	R	Rs	Rs	QS	qR	Rs	QS	V2–V3	120	0.97	0.67	18
4	53	F	VPC	R	Rs	RS	QS	rsR	Rs	QS	V2–V3	123	0.87	0.59	30
5	64	M	VPC	R	R	rs	QS	r	Rs	QS	V2–V3	122	0.63	0.51	24
6	68	M	NSVT	R	Rs	RS	QS	qR	Rs	QS	V2–V3	119	0.90	0.50	26
7	76	M	NSVT	R	R	RS	QS	qr	R	QS	V3–V4	128	0.70	0.66	20
8	62	F	VPC	R	R	rS	QS	R	Rs	QS	V3–V4	125	0.65	0.28	22
9	71	M	VPC	R	R	qrS	QS	R	qrS	QS	V3–V4	126	0.37	0.16	24
10	69	M	VPC	r	R	Rs	QS	qr	R	QS	V3–V4	120	0.78	0.65	20
11	67	F	VPC	R	R	Rs	QS	qR	Rs	QS	V2–V3	134	0.91	0.77	16
12	84	M	VPC	R	R	QS	QS	R	QS	QS	V3–V4	122	0.12	0	18
13	79	M	VPC	R	R	Rs	QS	rsr	Rs	QS	V2–V3	121	0.88	0.78	22
14	85	M	VPC	R	R	qrS	QS	R	qrS	QS	V2–V3	129	0.33	0.17	20
15	82	F	VPC	r	R	Rs	QS	qr	R	QS	V2–V3	119	0.89	0.5	28
16	64	F	VPC	R	Rs	rS	QS	rsR	Rs	QS	V2–V3	118	0.83	0.53	29
17	72	F	NSVT	R	R	rs	QS	R	R	QS	V3–V4	124	0.73	0.50	28

F, female; III/II ratio, the R-wave amplitude ratio in leads II and III; M, male; NSVT, non-sustained ventricular tachycardia; VPC, ventricular premature contraction; V-QRS His, the local ventricular activation time on the His bundle region relative to the surface QRS onset.

This Feature Is Available To Subscribers Only